. . . . . . . . . . . . "[Furthermore, the genomic fusion site in MLL rearrangements represent a unique and reliable molecular marker that allows the tracing of minimal residual disease (MRD) in these patients before, during, and after therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2016-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2016-05-13T12:47:14+02:00"^^ . . . . . . . . . . . "v4.0.0.0" . "v4.0.0" .